SINOVAC BIOTECH LTD (SVA) Form 20-F — Jun 5, 2026
Sinovac Biotech Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, disclosing material weaknesses in its internal control over financial reporting. Both management and the independent registered public accounting firm concluded that internal controls were not effective as of year-end, citing deficiencies that could lead to material misstatements in financial statements. The filing coincides with severe listing risks, as NASDAQ issued a delisting determination letter on May 22, 2026, due to the company's failure to timely file this annual report.
Key figures
- Eps
- 0
- Net Income
- 0
- Total Debt
- 0
- Shares Outstanding
- 71860702
- Revenue 2022
- 1500
- Revenue 2023
- 470.2
- Employees count
- 2602
- Rd expenses 2023
- 350.2
- Rd expenses 2024
- 270.7
- Rd expenses 2025
- 216.2
- Births china 2024
- 9.54
- Births china 2025
- 7.92
- Dividend per share 2025
- 55
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.